GenesisCare, Australia’s leading private provider of cardiac treatment services, is pleased to announce that promising results and improvement in patients’ mitral valve regurgitation are demonstrated in a recent outcomes report for the MAVERIC clinical trial. GenesisCare is currently enrolling patients to participate in this trial.
The trial is a major step forward for treating heart disease in Australia, potentially providing a new option for patients with mitral valve disease that are at high risk for open heart surgery. The commonest cause of a leaking mitral valve is congestive heart failure The world-first study explores the use of a new and less invasive, valve device using an innovative implantation technique.
The study’s 2 year outcomes report shows promising results and improvement in the patients’ mitral regurgitation. Find out more in the report.